A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
Key facts
- Who runs it
- Pfizer
- Where
- Los Angeles and St Louis, United StatesSee the 3 sitesAlso in 2 other countries, 6 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 10 people enrolled
- Started
- 15 Feb 2024
- Ended
- 3 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Placebo
- Active
- Record updated
- 30 December 2025
- Why it stopped
- Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study
Who can take part
- Age
- 1 day to 60 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 1 day to ≤60 months of age and weight ≥2.5 kg to ≤23 kg
- Positive RSV diagnostic test, antigen or molecular test
- Evidence of Lower Respiratory Tract Infection (LRTI)
Who cannot take part
- Expected to receive an antiviral for another viral infection within 10 days of screening
- Suspected or confirmed clinically significant moderate or severe bacterial infection that may interfere with the evaluation of response to the study intervention
- Premature infants (gestational age less than 35 weeks) AND <1 year of post-natal age
- Neonates with intrauterine growth restriction
- Known to have significant comorbidities that would limit the ability to administer the study intervention or evaluate the safety or clinical response to the study intervention
Where in United States
Also in 2 other countries, 6 sites
- Kaiser PermanenteLos Angeles, United States
- Kaiser Permanente Los Angeles Medical CenterLos Angeles, United States
- Washington University School of MedicineSt Louis, United States
About the trial
What the trial wants to find out
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months. These children have Lower Respiratory Tract Infection (LRTI) caused by Respiratory Syncytial Virus (RSV). LRTI is the infection to the lower airways such as lungs.
Read full original descriptionShow less
This study will help inform the amount of sisunatovir to be used in future studies of sisunatovir in children.
This study is seeking for participants who:
* Are 1 day to less than or equal to 60 months of age * weigh more than or equal to 2.5 kilograms to less than or equal to 23 kilograms. * Have been tested to have RSV by medical tests. * show signs of LRTI.
All participants in the study will receive many amounts of sisunatovir or placebo. Placebo is a pill that does not have any medicine in it.
Up to 7 visits are required for the study. Some of these visits include checking participants health over the phone and/or a visit at home.
The study will compare the experiences of infants and children receiving sisunatovir to identify the amount of sisunatovir to be used in future studies in infants and children.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Oral or Nasogastric tube (NG)
- SisunatovirExisting treatment, for comparison
Oral or NG tube
Treatment: Active
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- AN INTERVENTIONAL, PHASE 1b, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, MULTI-CENTER, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SISUNATOVIR IN PEDIATRIC PARTICIPANTS UP TO AGE 60 MONTHS WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) LOWER RESPIRATORY TRACT INFECTION (LRTI)
- Record updated
- 30 December 2025